IrsiCaixa AIDS Research Institute
Julia Garcia Prado is an accomplished researcher in the field of immunology with a robust academic and professional background. At IrsiCaixa AIDS Research Institute since 2010, Julia serves as the Group Leader of the Viral Immune Evasion and Vaccines Group (VIRIEVAC) and has held positions as both a Miguel Servet II and Miguel Servet I Researcher. Additionally, Julia has been the Scientific Director at Germans Trias i Pujol Research Institute (IGTP) since February 2019. Julia's prior experience includes serving as a Postdoctoral Researcher at the University of Oxford from 2006 to 2009. Julia obtained a degree in Biochemistry from Universidad de Oviedo (1995-1999) and a degree in Immunology, Biological and Biomedical Sciences from Universitat Autònoma de Barcelona (2001-2005).
This person is not in any teams
IrsiCaixa AIDS Research Institute
The IrsiCaixa AIDS Research Institute is an international landmark and leading centre for research into the eradication of HIV/AIDS and related diseases. IrsiCaixa researchers also tackle other biomedical challenges, such as those associated with the microbiome and emerging infectious diseases. IrsiCaixa was created as a private non-profit foundation in 1995 with the support of “la Caixa” Foundation and the Department of Health of the Generalitat of Catalonia. Its director is Dr. Bonaventura Clotet, who is also president of the Fight AIDS and Infectious Diseases Foundation and head of the Infectious Diseases Unit of the Germans Trias i Pujol University Hospital. IrsiCaixa is located in this hospital, next to the Fight AIDS and Infectious Diseases Foundation, which makes for a unique model of collaboration between researchers, healthcare professionals, patients and community representatives. This transfer of knowledge between key stakeholders makes for novel solutions that facilitate progress towards eradication of HIV infection. IrsiCaixa research is based on a combined strategy to eradicate AIDS, based on five strategic lines that include the development of vaccines and antibodies against HIV. The centre also participates in clinical trials to evaluate novel therapeutic strategies and cooperates with low-income countries in the global fight against the pandemic.